Patent application number | Description | Published |
20080312157 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 12-18-2008 |
20090036364 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 02-05-2009 |
20090286723 | Hybrid Polypeptides with Selectable Properties - The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 11-19-2009 |
20110136737 | DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties - The Present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 06-09-2011 |
20120253023 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 10-04-2012 |
20130137631 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 05-30-2013 |
20130196913 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 08-01-2013 |
20130281374 | DPP-IV RESISTANT GIP HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 10-24-2013 |
20140249299 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES - The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes. | 09-04-2014 |
Patent application number | Description | Published |
20090156493 | UROCORTIN-III AND USES THEREOF - A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2α or β. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor. | 06-18-2009 |
20100168021 | UROCORTIN PROTEINS AND USES THEREOF - A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn IL Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2. | 07-01-2010 |
20120270792 | UROCORTIN-III AND USES THEREOF - A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2α or β. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor. | 10-25-2012 |
20140004603 | UROCORTIN-III AND USES THEREOF | 01-02-2014 |
20140288161 | UROCORTIN-III AND USES THEREOF - A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2α or β. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor. | 09-25-2014 |
Patent application number | Description | Published |
20140012878 | DATA MINING SYSTEM FOR AGREEMENT COMPLIANCE CONTROLLED INFORMATION THROTTLE - Enables data mining of monitored information, activities, and agreements associated with a throttling system. An agreement includes one or more conditions to satisfy the agreement, such as one or more tasks or activities to be performed by an agreement performer or events that may be detected, and actions performed to enforce or assert the agreement such as controlling the electronic device and/or enabling or disabling or otherwise limiting, reducing or increasing the amount or type of information allowed with respect to any or all electronic devices associated with the agreement performer. | 01-09-2014 |
20140012977 | AGREEMENT COMPLIANCE CONTROLLED INFORMATION THROTTLE - Controls electronic devices and/or throttles electronic devices and/or information for electronic devices based on agreements or events or any combination thereof. An agreement includes one or more conditions to satisfy the agreement, such as one or more tasks or activities to be performed by an agreement performer or events that may be detected, and actions performed to enforce or assert the agreement such as controlling the electronic device and/or enabling or disabling or otherwise limiting, reducing or increasing the amount or type of information allowed with respect to any or all electronic devices associated with the agreement performer. For example, the system controls the electronic device and/or enables, disables or limits the amount or type of information on an electronic device, e.g., telephone, computer, game, television, vehicle based on whether the child has finished assigned homework, chores or extracurricular activities as specified as conditions of the agreement. | 01-09-2014 |
20140012978 | AGREEMENT COMPLIANCE CONTROLLED ELECTRONIC DEVICE THROTTLE - Controls electronic devices and/or throttles electronic devices and/or information for electronic devices based on agreements or events or any combination thereof. An agreement includes one or more conditions to satisfy the agreement, such as one or more tasks or activities to be performed by an agreement performer or events that may be detected, and actions performed to enforce or assert the agreement such as controlling the electronic device and/or enabling or disabling or otherwise limiting, reducing or increasing the amount or type of information allowed with respect to any or all electronic devices associated with the agreement performer. For example, the system controls the electronic device and/or enables, disables or limits the amount or type of information on an electronic device, e.g., telephone, computer, game, television, vehicle based on whether the child has finished assigned homework, chores or extracurricular activities as specified as conditions of the agreement. | 01-09-2014 |
20140207950 | SCHEDULE AND LOCATION RESPONSIVE AGREEMENT COMPLIANCE CONTROLLED INFORMATION THROTTLE - Controls electronic devices and/or throttles electronic devices and/or information for electronic devices based on agreements or events and/or based on schedule, location, time, or any combination thereof. An agreement includes condition(s) to satisfy the agreement, such as task(s) or activities to be performed by an agreement performer, for example based on a schedule and/or location, at a particular time, or time period, or, or events that may be detected, and actions performed to enforce or assert the agreement. Actions may include controlling the electronic device and/or at least partially enabling/disabling or otherwise limiting, reducing or increasing the amount or type of information allowed with respect to any or all electronic devices associated with the agreement performer. Embodiments may reduce or block information from particular sources during a scheduled school class to limit web surfing for information related to that class based on a schedule and/or location of the electronic device. | 07-24-2014 |
20140258512 | SCHEDULE AND LOCATION RESPONSIVE AGREEMENT COMPLIANCE CONTROLLED INFORMATION THROTTLE - Controls electronic devices and/or throttles electronic devices and/or information for electronic devices based on agreements or events and/or based on schedule, location, time, or any combination thereof. An agreement includes condition(s) to satisfy the agreement, such as task(s) or activities to be performed by an agreement performer, for example based on a schedule and/or location, at a particular time, or time period, or, or events that may be detected, and actions performed to enforce or assert the agreement. Actions may include controlling the electronic device and/or at least partially enabling/disabling or otherwise limiting, reducing or increasing the amount or type of information allowed with respect to any or all electronic devices associated with the agreement performer. Embodiments may reduce or block information from particular sources during a scheduled school class to limit web surfing for information related to that class based on a schedule and/or location of the electronic device. | 09-11-2014 |
Patent application number | Description | Published |
20090197582 | PLATFORM FOR MOBILE ADVERTISING AND MICROTARGETING OF PROMOTIONS - An end-to-end mobile advertising system characterizes user behavior (e.g., location, interaction with advertisements on a mobile communication device, etc.) in order to select micro-targeted advertisements. A marketplace platform handles the formatting required for presentation suitable for mobile communication devices in accordance with negotiated tags for a desired audience (“reach”), for a suitable number of presentations (“frequency”) and for an effective duration (“time”) within a particular scheduled window. A condition of schedule for a timed coupon advertisement campaign is supported. Effectiveness is gauged even in the instance of impression advertisements by monitoring user location and/or interaction with the communication device to see a change in behavior (e.g., does not go to a competitor as forecasted, does go to a location of the advertiser, calls the advertiser, clips the advertisement for future reference, etc.). The marketplace platform secures user identification for privacy reasons from advertising entities that provide the advertisements. | 08-06-2009 |
20090197616 | CRITICAL MASS BILLBOARD - A public advertisement display (e.g., billboard) is dynamically adjusted for advertising content in response to characterizing a viewing population. At least a subset of the viewing population carries a wireless networked device that can be associated with a user's identity as well as a location of the user. A user profile is developed based on behavior, collected demographic data, web browsing through other devices, etc. Advertising campaigns have royalty values based on the number of viewers of a particular characterization. Optimization of the royalty is dynamically determined based on determining a number of viewers and a characterization of at least a portion of the viewers. A targeted advertising campaign of reach-frequency-time per viewer can be satisfied at least in part by tracking these views for identified users. A marketplace platform depersonalizes tracking and royalty reports to advertisers to protect the users and encourage their participation in the tracking. | 08-06-2009 |
20090198579 | KEYWORD TRACKING FOR MICROTARGETING OF MOBILE ADVERTISING - An end-to-end mobile advertising system characterizes user behavior with regard to a mobile communication device in order to select micro-targeted advertisements. In particular, “keyword” usage in mobile applications can serve as a basis or augment a user behavioral profile. The types of keywords monitored address the particular user interface limitations and uses of a mobile communication device, such as dialed telephone messages, applets, or triglets downloaded, RSS feeds selected, and search terms or navigation links used in a wireless WAP. A marketplace platform handles the formatting required for presentation suitable for mobile communication devices in accordance with negotiated tags for a desired audience (“reach”), for a suitable number of presentations (“frequency”) and for an effective duration (“time”) within a particular scheduled window. Effectiveness is gauged even in the instance of impression advertisements by monitoring user location and/or interaction with the communication device to see a change in behavior. | 08-06-2009 |
20090199107 | PLATFORM FOR MOBILE ADVERTISING AND PERSISTENT MICROTARGETING OF PROMOTIONS - An end-to-end mobile advertising system characterizes user behavior (e.g., location, interaction with advertisements on a mobile communication device, etc.) in order to select micro-targeted advertisements. A marketplace platform handles the formatting required for presentation suitable for mobile communication devices in accordance with negotiated tags for a desired audience (“reach”), for a suitable number of presentations (“frequency”) and for an effective duration (“time”) within a particular scheduled window. Effectiveness is gauged even in the instance of impression advertisements by monitoring user location and/or interaction with the communication device to see a change in behavior (e.g., whether goes to a location of a competitor or advertiser, calls the advertiser, clips the advertisement, etc.). This effectiveness is further tracked across applications and/or platforms to capture reach, frequency, and duration of a particular advertising campaign for a user. The marketplace platform secures user identification for privacy reasons from advertising entities that provide the advertisements. | 08-06-2009 |
20090199114 | MULTIPLE ACTIONS AND ICONS FOR MOBILE ADVERTISING - On a mobile communication device there are many more possible workflows that could be followed given the available functions of that device. These may include, but are not limited to, “click to call”, “click to locate”, “click to SMS”, “click to send a picture”, “click to handle later”, and can be constrained only by the available and accessible functionality of the user's device. A list of actions to be made available associated with an advertisement are provided along with an iconic visual representation of those actions for the user to identify what the resultant workflow will be if they activate the action. The list can be presented as selectable actions within the advertisement, on a sub menu activated by a dedicated device key or assigned softkey, or directly activated by using dedicated device keys or assigned soft keys, or other user-to-device interaction methods. | 08-06-2009 |
20100004997 | METHODS AND APPARATUS FOR GENERATING USER PROFILE BASED ON PERIODIC LOCATION FIXES - Implementations relate to systems and methods for generating a user profile based on periodic location fixes. A cellular telephone or other mobile device captures location information via GPS or other capability. A location history can be generated from accumulated location fixes. The location history is then analyzed to detect the user's travel and dwell patterns. That information can be combined with business classification (e.g., SIC, etc.) or Point of Interest (POI) databases to identify a user's likely home, work, or other locations based on dwell-times, time of day, and other parameters. The user's age and gender can potentially be inferred based on types of locations visited, such as school locations. The user profile can be correlated with market segmentation databases to generate a marketing rating, such as a Nielsen or Claritas rating. Advertising, media, or other content can then be tailored to the user's individual location and demographic profiles. | 01-07-2010 |